Copyright 2018 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2017. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
Analyst Blog: Archive
Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.
RHHBY BMY MRK GILD
Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
by Zacks Equity Research
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
NVO VRTX GILD CELG
Strong Brands & Regions Aid Estee Lauder in (EL) Q4 Earnings
by Zacks Equity Research
Solid brand and regional performances drive Estee Lauder's (EL) Q4 results. Travel and online sales were also strong.
HELE EL CHEF SCI
Kimberly-Clark (KMB) Banks on FORCE Program to Offset Costs
by Zacks Equity Research
Kimberly-Clark's robust cost-saving efforts and regular innovation help the company outperform the industry over the past three months.
KMB OLLI WDFC HELE
Boston Properties Scales 52-Week High on Investors' Optimism
by Zacks Equity Research
Boston Properties' (BXP) premium assets are likely to experience solid demand on economic recovery and job-market improvement. However, rise in supply of office space is likely to impede growth.
BXP PSB WPC OUT
United Technologies to Offer Energy Saving Solutions to AWRG
by Zacks Equity Research
United Technologies' (UTX) business arm, EcoEnergy Insights, to make American West Restaurant Group's Pizza Hut restaurants more energy efficient with its IoT-based solutions.
UTX CSL FSS CR
People's United Ratings Affirmed by Moody's, Outlook Stable
by Zacks Equity Research
Moody's Investors Service affirms all the ratings of People's United (PBCT) and its subsidiaries. Moreover, the rating firm's outlook for the bank has been maintained at "stable".
CMA STI MCO PBCT
Is it Appropriate to Hold Mid-America Apartment Stock Now?
by Zacks Equity Research
Mid-America Apartment (MAA) caters to the largest segments of the apartment rental market. However, geographic concentration exposes the company to any economic doldrums prevailing in these regions.
MAA PSB OUT NRE
Texas Capital (TCBI) Displays Organic Growth: Time To Hold?
by Zacks Equity Research
Texas Capital Bancshares' (TCBI) robust organic growth highlights its upside potential. However, expenses continue to escalate.
TCBI BOKF BANF FFIN
Here's Why You Should Hold on to Praxair (PX) Stock for Now?
by Zacks Equity Research
Praxair (PX) to gain from growing energy and industrial end markets, strong backlog and new order wins despite concerns in Brazilian economy and a strong U.S. dollar.
PX APD CE HUN
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week dosing schedule.
SNY NVS BAYRY REGN
Selective Insurance Hits 52-Week High: Will the Trend Remain?
by Zacks Equity Research
Selective Insurance Group (SIGI) has hit 52-week high on Aug 17 on strong second-quarter 2018 earnings.
BRK.B ACGL AFG SIGI
Aetna (AET) Reaches 52-Week High on a Solid Second Quarter
by Zacks Equity Research
Aetna's (AET) shares scale a 52-week high on Aug 17, 2018 led by strong second-quarter performance.
AET UNH WCG ANTM
Why Total System (TSS) Stock Looks More Lucrative Right Now
by Zacks Equity Research
Total System (TSS) is poised to grow on the back of more frequent use of cashless technology in payments as well as flourish of small businesses.
CATM WEX TSS EVTC
Roche's Lung Cancer Drug Alecensa Gets Approval in China
by Zacks Equity Research
The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.
RHHBY BMY PFE ILMN
AES Corp Unveils Maiden LNG Terminal in Central America
by Zacks Equity Research
AES Corp (AES) plans to expand its LNG exports from the United States to Central America and the Caribbean in order to drive economic development in the regions.
CMS AES DTE AQN
Here's Why You Should Hold onto Canadian National (CNI) Now
by Zacks Equity Research
Canadian National's (CNI) view for 2018 on account of rising freight demand is encouraging.
SKYW TRN GATX CNI
GATX Stock Surges 35% Year to Date: What's Behind the Rally?
by Zacks Equity Research
GATX's efforts to reward shareholders raise optimism in the stock. Also, the company's decision to raise its full-year earnings outlook owing to improved market conditions is encouraging.
LUV GATX UNP NSC
Here's Why Investors Should Bet on Triton International Now
by Zacks Equity Research
Triton International's (TRTN) impressive bottom-line performance can be attributed to a lower tax rate. Moreover, its efforts to reward shareholders are encouraging.
LUV TRTN UNP NSC
GameStop (GME) Q2 Earnings Likely to Fall Y/Y: Here's Why
by Zacks Equity Research
GameStop (GME) is reeling from soft comps and sales, especially in the Technology Brands category, for the past few quarters. Also, bleak fiscal 2018 view is likely to hurt the company's bottom line.
FL BBY GME BIG
Here's Why You Should Scrap JetBlue From Your Portfolio Now
by Zacks Equity Research
Rising fuel prices as well as labor costs might hamper JetBlue's (JBLU) bottom line in the third quarter.
JBLU SKYW TRN GATX
Crown Holdings (CCK) Down 27% YTD: What's Pulling it Down?
by Zacks Equity Research
Crown Holdings (CCK) witnesses headwinds like elevated freight costs in North America and unfavorable foreign currency-translation, which have compelled the company to lower 2018 earnings guidance.
CCK ATU CAT LAWS
Will Higher Demand Aid Toll Brothers (TOL) in Q3 Earnings?
by Zacks Equity Research
Lack of competition in the luxury new home market and a positive housing market outlook are likely to boost Toll Brothers' (TOL) fiscal Q3 results.
PHM TOL DHI MTH
Google Joins Forces With GN Hearing, Gains Competitive Edge
by Zacks Equity Research
Alphabet's (GOOGL) Google introduces specification of audio streaming support for hearing aid users on android operating system.
ANGI MTCH GOOGL AAPL
Lockheed Martin Wins $26M Deal for Supporting F-35 Program
by Zacks Equity Research
Lockheed Martin's (LMT) Autonomic Logistics Information System helps the operators of the F-35 Lightning II aircraft to plan ahead, and maintain and sustain its systems over the life of the air vehicle.
LMT HII EGL AJRD